Regadenoson pharmacologic rubidium-82 PET: A comparison of quantitative perfusion and function to dipyridamole

Journal of Nuclear Cardiology

Volumn 20, Issue 1, 2013, Pages 76-83

  Cullom, S James ^a,c   Case, James A ^a   Courter, Staci A ^a   McGhie, A Iain ^b   Bateman, Timothy M ^a,b  

^a Cardiovascular Imaging Technologies LLC   (United States)

^b Cardiovascular Consultants Inc   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

coronary artery disease; pharmacological stress; positron emission tomography; regadenoson; Rubidium 82

Indexed keywords

DIPYRIDAMOLE; REGADENOSON; RUBIDIUM CHLORIDE RB 82;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART RATE; HUMAN; MALE; MYOCARDIAL PERFUSION IMAGING; PHARMACOLOGIC STRESS TESTING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE; BODY MASS INDEX; CHLORIDES; DIPYRIDAMOLE; EXERCISE TEST; FEMALE; HEMODYNAMICS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; PURINES; PYRAZOLES; RADIOPHARMACEUTICALS; RUBIDIUM; RUBIDIUM RADIOISOTOPES; VENTRICULAR FUNCTION, LEFT;

EID: 84872682035     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-012-9636-4     Document Type: Article

References (23)

1. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-20. (Pubitemid 47163555)
2. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58. (Pubitemid 47355078)
3. Zhoghbi GJ, Iskandrian AE. Selective adenosine agonists and myocardial perfusion imaging. J Nucl Card 2012;19:126-41.
4. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16. (Pubitemid 351676842)
5. Package Insert of l.V. Persantine (dipyridamole USP), February 1991.
6. Camp A, Chaitman BR, Goodgold H, et al. Intravenous dipyridamole and body weight considerations and dosage requirements. Am Heart J 1989;117:702-4. (Pubitemid 19078177)
7. Henzlova MJ, Cerqueira MD, Hansen CL, Taillefer R, Yao SS. Stress protocols and tracers, ASNC guidelines, J Nucl Cardiol 2009.
8. Cardiogen-82 Package Insert. Bracco Diagnostics Inc., 2012.
9. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006;13:24-33. (Pubitemid 43192726)
10. Cerqueira M, Weissman N, Dilsizian V, Jacobs A, Kaul S, Laskey W, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42. (Pubitemid 34262671)
11. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979;14;300:1350-8. (Pubitemid 9198112)
12. Hsu BL, Case JA, Moser KW, Bateman TM, Cullom SJ. Reconstruction of rapidly acquired Germanium-68 transmission scans for cardiac PET attenuation correction. J Nucl Cardiol 2007;14:706-14. (Pubitemid 47370877)
13. Hsu BL, Moser KW, Cullom SJ, Bateman TM, Helmuth PA, Case JA. Correction of imaging artifacts from implanted leads in cardiac PET/CT: A phantom evaluation. J Nucl Med 2005;46:174P.
14. Hsu BL, Moser KW, Cullom JS, Bateman TM, Heller GV, Case JA. A novel Bayesian reconstruction method to correct CT image artifacts in cardiac PET/CT. J Nucl Cardiol 2005;12:S57.
15. Slomka P, Nishina H, Berman D, Akincioglu C, Abidov A, Friedman J, et al. Automated quantification of myocardial perfusion SPECT using simplified normal limits. J Nucl Cardiol 2005;12:66-77.
16. Nakazato R, Berman DS, Dey D, Le Meunier L, Hayes SW, Fermin JS, et al. Automated quantitative Rb-82 3D PET/CT myocardial perfusion imaging: Normal limits and correlation with invasive coronary angiography. J Nucl Cardiol 2011;19:265-76.
17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;8476:307-10. (Pubitemid 16134762)
18. Everett B, Der G. Statistical analysis of medical data using SAS. 1st ed. London: Chapman and Hall/CRC; 2005.
19. Goudarzi B, Fukushima K, Bravo P, Merrill J, Bengel FM. Comparison of the myocardial blood flow response to regadenoson and dipyridamole: A quantitative analysis in patients referred for clinical Rb82 myocardial perfusion PET. Eur J Nucl Med Mol Imaging 2011;38:1908-16.
20. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008;15:329-36.
21. Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681-92.
22. Husain Z, Palani G, Cabrera R, Karthikeyan AS, Dhanalakota S, Pathmanathan S, Jacobsen G, Ananthasubramaniam K. Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Int J Cardiovasc Imaging 2012;28:1841-9.
23. Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 2012;19:319-29.